NASDAQ:ODTOdonate Therapeutics Stock Price, Forecast & News

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ODT stock has increased by 19.8% and is now trading at $31.06. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Odonate Therapeutics.

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Odonate Therapeutics.

Odonate Therapeutics Inc (NASDAQ:ODT) issued its earnings results on Tuesday, April, 28th. The company reported ($0.99) EPS for the quarter, beating the Zacks' consensus estimate of ($1.03) by $0.04. View Odonate Therapeutics' earnings history.

2 analysts have issued twelve-month price objectives for Odonate Therapeutics' stock. Their forecasts range from $26.00 to $26.00. On average, they anticipate Odonate Therapeutics' share price to reach $26.00 in the next year. This suggests that the stock has a possible downside of 16.3%. View analysts' price targets for Odonate Therapeutics.

News headlines about ODT stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Odonate Therapeutics earned a news sentiment score of -4.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutOdonate Therapeutics.

Odonate Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 714,100 shares, a decrease of 8.4% from the April 30th total of 779,900 shares. Based on an average daily volume of 77,400 shares, the days-to-cover ratio is currently 9.2 days. Approximately 2.5% of the company's shares are short sold. View Odonate Therapeutics' Current Options Chain.

Some companies that are related to Odonate Therapeutics include GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Allakos (ALLK), ChemoCentryx (CCXI), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Biohaven Pharmaceutical (BHVN), Deciphera Pharmaceuticals (DCPH), FibroGen (FGEN), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT), Axsome Therapeutics (AXSM) and Arena Pharmaceuticals (ARNA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), Fate Therapeutics (FATE), Bausch Health Companies (BHC), Five Prime Therapeutics (FPRX), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX) and Crispr Therapeutics (CRSP).

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Odonate Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (5.88%), Janus Henderson Group PLC (4.93%), Franklin Resources Inc. (3.62%), BlackRock Inc. (2.38%), Redmile Group LLC (2.21%) and Driehaus Capital Management LLC (2.20%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View institutional ownership trends for Odonate Therapeutics.

ODT stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Redmile Group LLC, Morgan Stanley, Franklin Resources Inc., State Street Corp, Pictet Asset Management Ltd., and UBS Group AG. View insider buying and selling activity for Odonate Therapeutics.

ODT stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Driehaus Capital Management LLC, Invesco Ltd., JPMorgan Chase & Co., Russell Investments Group Ltd., Geode Capital Management LLC, Eagle Asset Management Inc., and Chartwell Investment Partners LLC. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang. View insider buying and selling activity for Odonate Therapeutics.

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ODT stock can currently be purchased for approximately $31.06.

Odonate Therapeutics has a market capitalization of $997.34 million. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.

The official website for Odonate Therapeutics is www.odonate.com.

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]